Sanjivani Paranteral Ltd
Sanjivani Paranteral Q2 FY26 earnings call: Revenue & Margins
Q2 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.
From Sanjivani Paranteral Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions.
- Pune plant to start contributing commercially from Q3 FY '26, with full-year revenue potential of INR 90-110 crores.
- Optimal capacity utilization of the Pune plant expected by Q2 FY '27, potentially contributing INR 20-25 crores quarterly.
- Base business growth projected at 15-20% for the next year (FY '27), with total revenue expected around INR 150 crores.
- Alevia Healthcare joint venture is forecasted to contribute INR 1-1.5 crores to the bottom line in FY '26 and expected to grow at least 100% in FY '27 (INR 3-3.5 crores+).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.
- The company is modernizing its facilities, incorporating AI to enhance efficiency and cost-effectiveness.
- Development of import alternatives at the Pune plant is on track, with test licenses in place; products expected in the next 2-3 quarters.
- The Pune plant has started commercial production recently and is expected to contribute INR 90-110 crores revenue on full-year operation, hitting optimal capacity by Q2 FY '27.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- The Pune plant has a "very good healthy order book" in place, with commercial production started and business commencing from Q3 FY '26.
- Orders for the Pune plant come from semi-government, government institutions, and exports to 3-4 established geographies.
- Specific quantities of the Pune plant’s order book were not disclosed, with quantification to be provided later.
- Orders worth approximately INR 1 crore were held back due to local unrest in Nepal but have since been dispatched.
- Order books are reported to be good, supporting improved sales in the next two quarters.
2 more points management made on order book & pipeline
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanjiv.Parant.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q2 FY26)
248 Crores . Key concall takeaways from Morepen Laboratories Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Jubilant Pharmova Ltd (Q2 FY26)
Q2’FY26 revenue grew by 12% YoY to Rs. Key concall takeaways from Jubilant Pharmova Ltd's Q2 FY26 earnings call — and how it ranks against sector peers.
- Anuh Pharma Ltd (Q2 FY26)
185.88 Cr, a -0.32% change quarter-on-quarter; 6 months ended 30/09/2025: Rs. Key concall takeaways from Anuh Pharma Ltd's Q2 FY26 earnings call — and how it…
- Themis Medicare Ltd (Q2 FY26)
Q2 FY26 Net Revenue: ₹77.99 Cr, down 33.3% YoY from ₹117.01 Cr in Q2 FY25 (Page 8) . Key concall takeaways from Themis Medicare Ltd's Q2 FY26 earnings call…
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q2 FY26 results?
The company expects a minimum of 10% sales growth from the previous year, rebounding from recent disruptions. The company expects a minimum of 10% sales growth for FY '26 compared to the previous year.
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
In H1 FY '26, Sanjivani Paranteral Limited undertook a capex of INR 1.04 crores.
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.